Randomized, Multicenter, Open-label, Comparative Study of Efficacy and Safety of Treatment With a Calcineurin Inhibitor (CNI), Associating Myfortic and Neoral Compared to a CNI-free Treatment, Combining Myfortic and Certican , in Adult Patients With de Novo Renal Transplant

Trial Profile

Randomized, Multicenter, Open-label, Comparative Study of Efficacy and Safety of Treatment With a Calcineurin Inhibitor (CNI), Associating Myfortic and Neoral Compared to a CNI-free Treatment, Combining Myfortic and Certican , in Adult Patients With de Novo Renal Transplant

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2016

At a glance

  • Drugs Everolimus (Primary) ; Ciclosporin; Mycophenolate mofetil
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms CIME
  • Most Recent Events

    • 23 Jun 2016 Status changed from recruiting to active, no longer recruiting.
    • 25 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 May 2017.
    • 25 Apr 2016 Planned primary completion date changed from 1 Jul 2015 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top